A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally

NCT05572255 | Completed Phase 1 FDA Drug

• 1 other identifier: YKP3089C045
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a phase 1, randomized, open-label, single center, single-dose, 6-sequence, 3-period, 3-treatment crossover study in healthy adult male and female subjects to assess: the relative bioavailability of a crushed 200 mg, intact (whole) 200 mg and crushed 200 mg tablet via NG tube of cenobamate. All treatments will be administered under fasting conditions.

Conditions

Healthy Volunteers

Outcome Measures

Primary Outcomes (3)

• Cmax

  Maximum observed plasma concentration

  up to 38 days

• AUClast

  AUC from the time 0 to the time of last measurable concentration

  up to 38 days

• AUCinf (AUC0-inf)

  AUC from time 0 extrapolated to infinity

  up to 38 days

Secondary Outcomes (6)

• Safety and Tolerability - Adverse Events

  up to 45 days

• Safety and Tolerability - Clinical Laboratory Tests

  up to 45 days

• Safety and Tolerability - Vitals Signs

  up to 45 days

• Safety and Tolerability - Physical Examination

  up to 45 days

• Safety and Tolerability - ECG

  up to 45 days

Study Arms (3)

Treatment A (Reference)

EXPERIMENTAL

An intact 200 mg cenobamate tablet administered orally.

Drug: Cenobamate

Treatment B (Test 1)

EXPERIMENTAL

A crushed 200 mg cenobamate tablet in suspension administrated orally.

Drug: Cenobamate

Treatment C (Test 2)

EXPERIMENTAL

A crushed 200 mg cenobamate tablet in suspension administered via an NG tube

Drug: Cenobamate

Interventions

Cenobamate DRUG

200 mg Cenobamate Tablet

Also known as: YKP3089C045

Treatment A (Reference); Treatment B (Test 1); Treatment C (Test 2)

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male or female subjects of 18 to 50 years of age (inclusive), at the time of screening
• Able to read, understand, sign, and date a written informed consent form (ICF) before study participation at screening
• Agree to use effective methods of contraception as described
• Body mass index (BMI) between 18.5 and 30.0 kg/m2 (inclusive) at screening
• In good health on the basis of medical history, physical examination, and routine laboratory measurements (i.e., without clinically relevant pathology)
• Electrocardiogram (ECG) (12-lead), arterial blood pressure, and heart rate within the normal range of the study center or considered not clinically significant by the Investigator.
• Able to understand and comply with protocol requirements and instructions and likely to complete the study as planned
• Females of non-childbearing potential who have undergone a surgical sterilization procedure at least 6 months prior to dosing with official documentation (e.g., bilateral tubal ligation or bilateral salpingectomy or hysterectomy), or be postmenopausal with amenorrhea for at least 1 year prior to dosing and follicle-stimulating hormone (FSH) serum levels consistent with postmenopausal status as per Principal Investigator's judgment

You may not qualify if:

• Clinically relevant abnormal medical history, abnormal findings on physical examination, vital signs, ECG, or laboratory tests at Screening that the Investigator judges as likely to interfere with the objectives of the trial or the safety of the volunteer.
• History of nasal obstructions or nasal allergies
• Smokers, including vaping (subjects who have smoked within 6 months at screening)
• History of any drug related hypersensitivity reactions as well as severe hypersensitivity reactions (like angioedema) or DRESS as evaluated by the Investigator
• Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with pharmacokinetics of the study drug (except appendectomy and simple hernia repair)
• Any prescribed or over-the-counter medication taken within 2 weeks prior to start of administration of study drug (Day 1) or within 6 times the elimination half-life of the prescribed or over-the-counter medication prior to start of study drug intake (whichever is longer). Occasional use of acetaminophen is allowed up until 24 hours before dosing
• Consumption of herbal medications, dietary supplements, and specific fruit products. Subjects should have stopped consumption of herbal medications or dietary supplements (e.g., St. John's Wort, ginkgo biloba, and garlic supplements), and grapefruit or grapefruit juice, or Seville oranges at least 2 weeks before the first dosing day of study drug. Vitamins/mineral supplements are allowed up until 24 hours before dosing
• History of drug or alcohol abuse or addiction within 2 years before the start of study drug dosing, or a positive test results for alcohol or drugs of abuse, such as amphetamine, barbiturate, benzodiazepine, cocaine, methadone, opiates, oxycodone, phencyclidine, propoxyphene, cannabinoid (THC), MDMA (Ecstasy), cotinine, and tricyclic antidepressant (TCA)
• Regular consumption of more than 2 units of alcoholic beverages per day or more than 14 units per week (1 unit of alcohol equals 1 pint \[473 mL\] of beer or lager, 1 glass \[125 mL\] of wine, 25 mL shot of 40% spirit) before screening
• Consumption of an average of more than 5 servings (8 ounces per serving) per day of coffee, cola, or other caffeinated or methyl xanthine beverages before screening
• Consumption of any caffeine- or methyl xanthine-containing products (e.g., coffee, tea, chocolate, or soda) or alcoholic beverages within 48 hours prior to Day 1 of each period and until the end of each PK sampling period
• Participation in a clinical study involving administration of either an investigational or a marketed drug within 2 months or 7 half-lives (whichever is longer) before screening
• Blood donation or a significant loss of blood within 60 days of the start of study drug dosing or donation of more than 1 unit of plasma within 7 days before screening
• Positive result at screening for any of the following infectious disease tests: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), human immunodeficiency virus antigen and antibody (HIV Ag, HIV Ab)
• Illness within 5 days before the start of study drug dosing ("illness" is defined as an acute \[serious or non-serious\] condition \[e.g., the flu or the common cold\])

Sponsors & Collaborators

• SK Life Science, Inc.: lead

Study Sites (1)

Worldwide Clinical Trials

San Antonio, Texas, 78217, United States

Location

MeSH Terms

Interventions

Cenobamate

Study Officials

• Vijaykumar Vashi

  SKLSI

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Single-dose, 6-sequence, 3-period, 3-treatment crossover study

Study Record Dates

• First Submitted: September 30, 2022
• First Posted: October 7, 2022
• Study Start: September 27, 2022
• Primary Completion: January 28, 2023
• Study Completion: January 28, 2023
• Last Updated: September 19, 2024

Record last verified: 2024-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)